FinnCap Reaffirms Buy Rating for Shield Therapeutics PLC (STX)
Shield Therapeutics PLC (LON:STX)‘s stock had its “buy” rating restated by equities research analysts at FinnCap in a note issued to investors on Thursday. They presently have a GBX 270 ($3.49) price target on the stock. FinnCap’s target price suggests a potential upside of 71.43% from the company’s previous close.
STX has been the topic of a number of other research reports. Liberum Capital reaffirmed a “buy” rating and issued a GBX 245 ($3.16) price target on shares of Shield Therapeutics PLC in a research report on Thursday. Peel Hunt reaffirmed a “buy” rating and issued a GBX 220 ($2.84) price target on shares of Shield Therapeutics PLC in a research report on Thursday, July 6th.
Shares of Shield Therapeutics PLC (LON:STX) remained flat at GBX 157.50 during trading on Thursday. The stock had a trading volume of 2,500 shares. The stock’s market cap is GBX 170.10 million. The company has a 50-day moving average price of GBX 157.50 and a 200-day moving average price of GBX 163.10. Shield Therapeutics PLC has a 12 month low of GBX 152.25 and a 12 month high of GBX 177.00.
About Shield Therapeutics PLC
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.
Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.